

Haematologica
HAEMATOL/2019/222828
Version 3

Accuracy of the Ottawa score in risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism. A systematic review and meta-analysis.

Aurélien Delluc, Sébastien Miranda, Paul den Exter, Martha Louzada, Adriano Alatri, Shin Ahn, Manuel Monreal, Alok Khorana, Menno V. Huisman, Philip S. Wells, and Marc Carrier

Disclosures: Dr. Aurelien Delluc reports he has participated as a member of Advisory Board for Sanofi Aventis, Leo Pharma, Bayer, Servier Canada, and Pfizer/Bristol-Myers Squibb, has received speaker honoraria from Bayer, Pfizer/Bristol-Myers Squibb, LEO Pharma, and is participating in or has participated in a clinical trial within the past two years with Leo Pharma, Bristol-Myers Squibb, Bayer Dr. Khorana reports consulting fees and honoraria from Bayer, Janssen, Pfizer, Halozyme, Seattle Genetics, and AngioDynamics that are outside the scope of the submitted work. Dr. Wells reports personal fees from Bayer Healthcare, Itreas, Janssen, Pfizer, BMS, Sanofi, Medscape Servier Canada and Grant support fees from Bayer Healthcare and Pfizer/BMS Dr. Carrier reports Research Funding from BMS, Pfizer, Leo Pharma, and Honoraria from BMS, Pfizer, Bayer, Servier, Leo Pharma, Sanofi.

Contributions: Contributions: AD, SM, and MC performed the research, analysed data, performed data analysis and wrote the manuscript. PDE, ML, AA, SA, MM, AK, MVH, and PSW performed the research, interpreted the data, and provided critical review of the manuscript.